Drug Pipeline
Having completed pre-clinical & formulation work with the University of Toronto, we are advancing to late-stage clinic development in two primary areas: Clinical High Risk for Psychosis & General Anxiety Disorder.

Having completed pre-clinical & formulation work with the University of Toronto, we are advancing to late-stage clinic development in two primary areas: Clinical High Risk for Psychosis & General Anxiety Disorder.